Graphene Oxide as a Carrier for Drug Delivery of Methotrexate

Hani Nasser Abdelhamid 1*, Kamal Hany Hussein 2

1 Advanced Multifunctional Materials Laboratory, Department of Chemistry, Faculty of Science, Assiut University, Assiut, Egypt
2 Department of Animal Surgery, Anaesthesia, and Radiology, Faculty of Veterinary Medicine, Assiut University, Assiut 71526, Egypt.

* Correspondence: hany.abdelhamid@aun.edu.eg (H.N.A.);
Scopus Author ID 55370888300

Received: 2.02.2021; Revised: 10.03.2021; Accepted: 14.03.2021; Published: 31.03.2021

Abstract: Nanomaterials, including carbon-based nanoparticles, have been applied as carriers for anticancer drugs. This short communication reported the synthesis, cytotoxicity, and drug delivery of methotrexate using graphene oxide (GO) as a carrier. GO was synthesized following Hummer’s method. It was characterized using X-ray diffraction (XRD), transmission electron microscope (TEM), and scanning electron microscope (SEM). Data analysis confirms the synthesis of GO with high crystallinity and lamellae morphology. GO showed a high cytocompatibility toward the human EA.hy926 endothelial cells. GO has been used as a carrier for the anticancer drug; methotrexate. The drug delivery was tested for hepatocellular carcinoma cells (HepG2 cells), human embryonic kidney cells (HEK293A cells), and porcine skin fibroblasts (PEF).

Keywords: carbon nanomaterials; drug delivery; chemotherapy; methotrexate.

© 2021 by the authors. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

1. Introduction

Cancer disease has been considered a severe threat to humans. The World Health Organization (WHO, 2018) reported that cancer causes one in six deaths. According to a study in 2020, there are 19 million cases related to cancer annually [1], causing 8.8 million deaths (represents 15.7% of deaths annually) [2,3]. Several drugs have been reported as promising anticancer therapeutics [4–11]. However, they lack high cell internalization, cell permeation, bioavailability, selectivity, and increased efficiencies [5,6,12–19]. Thus, several carriers, including natural polymers [20], polysaccharides [13], magnetic carriers [21], and extracellular vehicles (EVs)[22], were reported for drug delivery. They exhibit high drug loading capability, controlled release, and increased cell internalization. Nanotechnology has advanced biomedical fields, including cancer treatment [23–29].

Graphene is a new allotrope (two-dimensional, 2D) of carbon nanomaterials with a single layer of $sp^2$-hybridized carbon atoms [30–39]. The synthesis of graphene was awarded Nobel Prize in Chemistry in 2010. Graphene-based nanomaterials such as graphene oxide(GO) have advanced biomedicine, including drug delivery [40,42]. They can proceed into scaffold [43,45], fiber [46], and hydrogels [47]. Graphene-based materials offered several advantages, including high drug loading and release abilities [47]. Mixed anticancer drugs such as doxorubicin (DOX) and camptothecin (CPT) can be loaded into GO [49]. Thus, they can deliver more than one drug simultaneously. The drug can be loaded to graphene via covalent
through cross-linking chemistry [50], electrostatic, and physical absorption interactions such as π-π cooperative interaction [51]. The drug delivery can be controlled via pH [50,52], enzymatic [53], Near-infrared (NIR) light [54], and electrically control [55]. The surface modification ensures high drug release [56]. Graphene can also be modified with other nanoparticles, including magnetic nanoparticles for photothermal treatment [57]. Graphene-based materials offer multifunctionality [58–61]. The polar groups render the material highly hydrophilic. Thus, they were used as a carrier for the delivery of anticancer drugs such as DOX [62], quercetin and gefitinib [63], sumatriptan succinate (SS) [64], and cytarabine (CYT) [65].

Herein, the application of graphene oxide (GO) to deliver methotrexate (MTX) was investigated. Hummer's method was followed to synthesis GO followed by ultrasonication to ensure high dispersion. The crystallinity and morphology of GO were characterized using X-ray diffraction (XRD) and electron microscope (transmission (TEM), scanning (SEM)). The material was mixed with methotrexate. Methotrexate-loaded GO was tested using hepatocellular carcinoma cells (HepG2 cells), human embryonic kidney cells (HEK293A cells), and porcine skin fibroblasts (PEF).

2. Materials and Methods

Graphite flakes were purchased from Alfa Aeser (Germany). 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT), sulfuric acid, and potassium permanganate (KMnO₄) were purchased from Sigma-Aldrich (USA).

2.1. Synthesis of GO.

GO was prepared using Hummer's method [32,66]. Natural graphite (1.0 g) was dispersed into a mixture of sulfuric acid (15.0 mL) and nitric acid (10.0 mL) in an ice-bath. Potassium permanganate (3.0 g) was gradually added to the acid mixture during stirring. After 12h, hydrogen peroxide (15.0 mL) was dropped. GO was collected and washed with HCl and water to remove any impurities. The solution of GO (1 mg/mL) was prepared via ultrasonication (140 W) for 2d at 60 °C.

2.2. Instruments.

X-ray diffraction (XRD) was recorded using a PANalytical X'Pert Pro diffractometer (Cu Ka1, λ of 1.54Å). Transmission electron microscopy (TEM) image was captured using a JEM-2100 instrument (JEOL, Japan). Scanning electron microscopy (SEM) image was performed using a JSM-7000 instrument (JEOL). UV-Vis spectra were recorded using Thermo Scientific Evolution-300. Fourier transform infrared (FT-IR) spectra were evaluated in solid form using Shimadzu-470 via the KBr disc technique.

2.3. Indirect cytotoxicity assay.

Human EA.hy926 endothelial cells were cultured in Dulbecco's modified Eagle medium (DMEM; Invitrogen, USA) supplemented with 10% fetal bovine serum (FBS; Hyclone, USA) and 1% penicillin/streptomycin (p/s, Gibco, USA) in a humidified incubator at 37°C and 5% CO₂. The cells were harvested using the trypsin-based method. Extracts were prepared from the GO to investigate any potential toxicological risk. The substrate was sterilized using ethylene oxide gas and mixed with serum-free DMEM supplemented with 1% p/s culture medium under the condition of 37°C/120 r/min for 72 h, according to a ratio.
standard of 0.2 g/mL of culture medium [67]. Then, the supernatant was centrifuged and filtered to prepare the preconditioned media finally.

Cells were cultured at a density of 5x10^4 cells/well in 24 well-plates for 24 h using a complete culture medium. The medium was aspirated, then 500 µL of conditioned or control medium was added after combining 10% FBS. As a negative control, cells were cultured with DMEM, while in the positive control wells, the cells were cultured in the presence of 20% dimethyl sulfoxide (DMSO). Cell viability was qualitatively investigated on day 3 using a Live/Dead assay kit (calcein-AM/ethidium Bromide homodimer, Invitrogen), according to the manufacturer's instructions, being viewed under a fluorescence microscope (Olympus, Japan).

2.4. Drug loading.

The anticancer drug was loaded by adding 1.0 mL of methotrexate (100 µg/mL; Sigma-Aldrich) to 4.0 mL of GO in buffer solution (25 µg/mL) under stirring for 48 hours in the dark at room temperature.

2.5. Drug delivery testing.

Hepatocellular carcinoma cells (HepG2 cells), human embryonic kidney cells (HEK293A cells), and porcine skin fibroblasts (PEF) were cultured in DMEM supplemented with 10% FBS in a humidified 5% CO2 atmosphere inside an incubator at 37°C. The cells were harvested from 90% confluent cell culture plates and were resuspended in a completely fresh medium before plating. The cells (3×10^4) were seeded in a 24-well plate. The cells were cultured for 24 hours, washed twice with phosphate-buffered saline (PBS), and then incubated with either MTX–GO, or MTX (20 µg/mL), or GO (20 µg/mL) only containing DMEM medium at 37°C for 24 hours. The cell viability was evaluated using the MTT assay. Active cells reduce yellow-colored MTT to purple-colored formazan dye crystals. Briefly, 50 µL of MTT solution (5 mg/mL) was added to each well and incubated at 37°C for 4 hours. After discarding the medium containing MTT, 350 µL of the cells were cultured in the presence of 20% DMSO. After 10 minutes of incubation, 100 µL aliquots from the wells were pipette into another 96-well plate. The color developed was quantified by recording the absorbance at a wavelength of 570 nm with a spectrophotometer.

3. Results and Discussion

3.1. Material characterization.

GO was synthesized through graphite oxidation using KMnO4 in an acidic solution (Figure 1) [39,68,69]. XRD pattern for GO exhibits a strong Bragg's diffraction peak at 10.9° corresponding to Miller index of (002) plane (Figure 2a). The d-spacing for the prepared material is 0.9 nm (Figure 2a). The morphology of GO was evaluated using TEM and SEM images (Figure 3). The transparency of GO in the TEM image reveals that GO consists of a few 2D layers (Figure 3a). SEM images confirm the lamellae morphology of GO (Figure 3b). The TEM and SEM images reveal that GO has crumbling morphology (Figure 3).

UV-Vis spectrum of GO shows maximum absorption bands at 250 nm and 355 nm corresponding to π→π* transition of aromatic C–C bonds and n→π* transition of C = C (Figure 2b) [70]. Based on the chemical structure, MTX shows strong π→π* or σ→σ* transition in the UV–Vis region at maximum absorbance of 368 nm and 274 nm (Figure 2b). The ultimate
The absorbance band of MTX at 368 nm was shifted to 361 nm after conjugation with GO indicating the strong interaction between GO and MTX.

![Figure 1](image)

**Figure 1.** Schematic representation for the synthesis of GO and loading of methotrexate for drug delivery.

The chemical function groups before and after the interactions were characterized using FT-IR spectra (Figure 2c). GO exhibits vibrational bands at 3569 cm\(^{-1}\), 1707 cm\(^{-1}\), 1628 cm\(^{-1}\), and 1029 cm\(^{-1}\); corresponding to O–H stretching, C=O stretching of the carboxylic acid groups, aromatic C–C stretching, O–H deformation, and the C–O (Figure 2c). The FT-IR spectrum of MTX shows the characteristic bands at 1380 cm\(^{-1}\), 1644 cm\(^{-1}\), and 3400 cm\(^{-1}\); corresponding to C–N, –NH\(_2\), and N–H, respectively (Figure 2c). MTX-GO exhibits the characteristic features for both materials. However, the vibrational bands of MTX mainly disappear, indicating the strong interaction with GO (Figure 2c).

![Figure 2](image)

**Figure 2.** (a) XRD pattern of GO; (b) UV-Vis spectra for GO, MTX, and MTX-GO; (c) FT-IR spectra for GO, MTX, and MTX-GO.
3.2. GO cytocompatibility.

The fluorescence images of EA.hy926 cells were also reported (Figure 4). Images indicate high cell density revealing the high biocompatible nature of GO (Figure 4).

3.3. Drug delivery.

GO was used for the delivery of methotrexate (Figure 1). Both sides of GO layers can adsorb MTX via non-covalent interactions including electrostatic, and π-π intercalation. The GO layers' interplanar distance is close to 1 nm, which offers MTX intercalation between the layers. Thus, GO can be used as a carrier for the delivery of MTX. The loading of MTX onto GO was achieved by mixing both species in an aqueous solution with sonication aid. The drug release was evaluated using HepG2, HEK293A, and PEF cells.
The MTT assay showed that the bare GO does not cause any considerable cytotoxic effect to the three cell types; HepG2, HEK293A, and PEF cells (Figure 5). The free MTX was taken up by the tumor cell line (HepG2 cells) and the normal cells (HEK293A and PEF cells) with almost similar cytotoxicity to all three cell types without apparent selectivity. After conjugating the MTX to GO as a carrier, the MTX-GO displayed significant specific cytotoxicity to the tumor cell line (HepG2 cells) compared to the normal cells (HEK293A and PEF cells). The results may open new avenues for using GO-based materials for clinical and surgery applications [71–74].

4. Conclusions

GO has been synthesized and applied as a carrier for the delivery of methotrexate. It exhibits high biocompatibility. The drug loading is simple. The cell viability for HepG2, HEK293A, and PEF cells showed controlled release. These findings open new opportunities for the biomedical applications of graphene oxide as a carrier for drug delivery.

Funding

This research has no funding.

Acknowledgments

This research has no acknowledgment.

Conflicts of Interest

The authors declare no conflict of interest.

References


42. Croitoru, A; Oprea, O; Nicoara, A; Trusca, R; Radu, M; Neacsu, I. A; Fical, D; Fical, A; and Andronescu, E; "Multifunctional Platforms Based on Graphene Oxide and Natural Products" *Medicina (Kaunas)*, **2019**, *55*, 6, 2019, doi: 10.3390/medicina55060230.


49. Zhang, L.; Xia, J.; Zhao, Q.; Liu, L.; Zhang, Z. Functional Graphene Oxide as a Nanocarrier for Controlled


55. Weaver, C.L.; LaRosa, JM; Luo, X.; Cui, X.T. Electrically Controlled Drug Delivery from Graphene Oxide Nanocomposite Films. ACS Nano 2014, 8, 1834-1843, https://doi.org/10.1021/nn406223e.


